^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
golcadomide (CC-99282)
i
Other names: CC-99282, BMS-986369, BMS986369, CC99282, BMS 986369, CC 99282
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
Cereblon modulator, CRL4-CRBN E3 ubiquitin ligase modulator
Related drugs:
7d
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse (clinicaltrials.gov)
P2, N=65, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Oct 2027 --> Dec 2028 | Trial primary completion date: Jan 2026 --> Mar 2027
Trial completion date • Trial primary completion date
|
golcadomide (CC-99282)
14d
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas (clinicaltrials.gov)
P1, N=18, Not yet recruiting, Allison Winter
New P1 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
Rituxan (rituximab) • pemetrexed • dexamethasone • golcadomide (CC-99282)
1m
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P1/2, N=58, Not yet recruiting, City of Hope Medical Center
New P1/2 trial
|
Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
2ms
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy (clinicaltrials.gov)
P1/2, N=0, Withdrawn, University of Pittsburgh | N=30 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
Opdivo (nivolumab) • golcadomide (CC-99282)
2ms
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
P2, N=33, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
|
Gazyva (obinutuzumab) • golcadomide (CC-99282)
2ms
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
Enrollment closed
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
|
golcadomide (CC-99282)
3ms
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=18, Recruiting, Nathan Denlinger | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
clonoSEQ®
|
Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
4ms
GOLSEEK-1: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (clinicaltrials.gov)
P3, N=850, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
Enrollment closed
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • golcadomide (CC-99282)
4ms
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (clinicaltrials.gov)
P1/2, N=49, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting
Enrollment open
|
azacitidine • golcadomide (CC-99282) • roginolisib (IOA-244)
5ms
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment (clinicaltrials.gov)
P1, N=29, Completed, Celgene | Recruiting --> Completed
Trial completion
|
golcadomide (CC-99282)
5ms
GOLSEEK-2: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (clinicaltrials.gov)
P2, N=90, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
Enrollment closed
|
Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • bendamustine • golcadomide (CC-99282)
6ms
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
P2, N=36, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
Trial primary completion date
|
Gazyva (obinutuzumab) • golcadomide (CC-99282)
Share via
